Back to top
more

Bausch Health (BHC)

(Delayed Data from NYSE)

$8.71 USD

8.71
2,081,596

+0.09 (1.04%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $8.72 +0.01 (0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 38% (95 out of 252)

Industry: Medical - Generic Drugs

Better trading starts here.

Zacks News

Bausch's (BHC) Q2 Earnings Beat Estimates, Revenues Miss

Bausch (BHC) beats on earnings but misses on sales in the second quarter. The company also lowers its annual revenue guidance.

Bausch Health (BHC) Tops Q2 Earnings Estimates

Bausch (BHC) delivered earnings and revenue surprises of 1.03% and -0.97%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Why Bausch (BHC) Might Surprise This Earnings Season

Bausch (BHC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Ekta Bagri headshot

4 Pharma/Biotech Stocks Poised to Beat on Earnings in Q2

We take a look at a few pharma/biotech companies, which are poised to beat on earnings in the second quarter.

Why Bausch (BHC) is Poised to Beat Earnings Estimates Again

Bausch (BHC) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Bausch Health (BHC) Earnings Expected to Grow: Should You Buy?

Bausch (BHC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Ardelyx (ARDX) Tumbles Following Deficiencies in Tenapanor NDA

The FDA notes deficiencies in the NDA seeking approval for Ardelyx's (ARDX) lead pipeline candidate, tenapanor, as a potential treatment for hyperphosphatemia.

Why Is Bausch (BHC) Up 13.8% Since Last Earnings Report?

Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Bausch's (BHC) Q1 Earnings Beat Estimates, Revenues Miss

Bausch (BHC) beats on earnings but misses on sales in the first quarter due to the ongoing pandemic.

Bausch Health (BHC) Beats Q1 Earnings Estimates

Bausch (BHC) delivered earnings and revenue surprises of 10.64% and -2.10%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Indrajit Bandyopadhyay headshot

3 Generic Drug Stocks to Watch Amid COVID-Related Recovery

The impact of the coronavirus pandemic on the Zacks Medical-Generic Drugs industry is expected to recede in 2021. Moreover, stable pricing and improving demand in some countries in 2021 may bode well for RDY, BHC and AMPH.

Why Is Bausch (BHC) Down 0.6% Since Last Earnings Report?

Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Bausch's (BHC) Q4 Earnings and Revenues Surpass Estimates

Bausch (BHC) reports better-than-expected results for the fourth quarter as the business shows recovery signs from the COVID-19 pandemic.

Bausch Health (BHC) Q4 Earnings Beat Estimates

Bausch (BHC) delivered earnings and revenue surprises of 19.82% and -0.23%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Should You Buy Bausch Health (BHC) Ahead of Earnings?

Bausch Health (BHC) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Bausch Health (BHC) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Bausch (BHC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tilray (TLRY) to Report Q4 Earnings: What's in the Cards?

Investors will focus on revenue growth and other pipeline updates, when Tilray (TLRY) reports fourth-quarter 2020 results.

What's in Store for Zomedica (ZOM)This Earnings Season?

Zomedica (ZOM) may provide an update on Truforma commercialization progress when it reports fourth-quarter 2020 results.

What's in Store for Mallinckrodt (MNKKQ)This Earnings Season?

Negative impact of COVID-19 is likely to have hurt sales of Mallinckrodt (MNKKQ) during the fourth quarter. Investors are likely to focus on bankruptcy proceedings during the earning call.

TEVA Gears Up to Report Q4 Earnings: What's in the Cards?

On TEVA's fourth-quarter conference call, investors focus is likely to be on updates on the extent to which the resurgence of COVID-19 infection rates impacted sales of its products.

Humana (HUM) to Report Q4 Earnings: What's in the Cards?

Humana's (HUM) fourth-quarter 2020 earnings might have endured escalating COVID-related expenses, partly offset by better revenues.

Bausch Health (BHC) Dry Eye Treatment Study Enrollment Complete

Bausch Health (BHC) and Novaliq GmbH complete enrollment in first of the two phase III studies evaluating NOV03 to treat the signs and symptoms of Dry eye disease associated with MGD.

Why Is Bausch (BHC) Up 13.3% Since Last Earnings Report?

Bausch (BHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

3 Generic Drug Stocks to Watch Amid COVID-Induced Uncertainty

The impact of the coronavirus pandemic on the Zacks Medical-Generic Drugs industry is difficult to gauge. However, stable pricing and improvement in demand in some countries in 2021 may bode well for RDY, BHC and VTRS.

Bausch (BHC) Begins Second Phase III Study on NOV03 for DED

Bausch (BHC) starts a second phase III study on its investigational treatment NOV03 for dry eye disease related to Meibomian gland dysfunction.